Dr. Maloney on the Value of CAR T Cells in Relapsed/Refractory Aggressive Lymphomas

Video

David G. Maloney, MD, PhD, discusses the value of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive lymphomas.

David G. Maloney, MD, PhD, medical director of the Immunotherapy Clinic and Program, Fred Hutchinson Cancer Research Center, discusses the value of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory aggressive lymphomas.

Many studies are currently trying to move CAR T-cell therapy forward in the treatment landscape, and 3 randomized trials are challenging the role of transplant after first relapse. Maloney says the trials show that tumor burden matters, so physicians should refer patients to centers that have access to either of the 2 approved CAR T-cell therapies.

Trials have also shown that patients treated with CAR T-cell therapy before widespread bulky disease, they will have a higher response duration. If we can treat the lowest disease burden with CAR T cells, Maloney says we will see better outcomes, longer survival, and a greater chance of remission 2 years later.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.